Using CAR T cells that target multiple antigens to treat acute myeloid leukemia
Official title: Multi-antigen-specific CAR T cells to treat acute myeloid leukemia
Funded at Beckman Research Institute/city of Hope · NIH-11142746 · Data updated 2026-11-12
This study is testing a new kind of CAR T cell therapy designed to help people with acute myeloid leukemia (AML) by training their immune cells to better recognize and fight the cancer, with the hope of improving treatment success and lowering the risk of the cancer coming back.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $263,034 |
| NIH project number | 7K08CA252157-05 |
| Project ID | NIH-11142746 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with acute myeloid leukemia who have not responded to standard treatments.
✕Less likely to help
Patients with other types of leukemia or those who are not eligible for CAR T cell therapy may not benefit from this research.
What this research studies
This research focuses on developing a new type of CAR T cell therapy that targets multiple antigens to treat acute myeloid leukemia (AML). The approach involves modifying T cells to recognize and attack cancer cells more effectively, especially since AML can vary greatly in its antigen expression. By using a novel system to create and purify these multi-antigen-specific T cells, the research aims to improve treatment outcomes and reduce the chances of cancer relapse. Patients will be monitored for their response to this innovative therapy.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with acute myeloid leukemia, potentially improving survival rates.
How similar studies have gone: Other research has shown promising results with CAR T cell therapies targeting single antigens, but this multi-antigen approach is relatively novel and untested.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: James, Scott E — Beckman Research Institute/city of Hope
- Study coordinator: James, Scott E
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.